Quick Read
Pulmonary hypertension is not one disease. It is a haemodynamic state in which pressure in the pulmonary circulation is elevated, and the reason for that elevation determines treatment. The cause may lie primarily in the pulmonary arteries, the left heart, the lungs and oxygenation, chronic blood clots, or other systemic conditions.
The distinct Medicine Web job is: breathlessness/syncope/right-heart strain or incidental pressure signal → echocardiographic and clinical suspicion → classify likely pulmonary-hypertension group → confirm haemodynamics where required → identify cause → risk-stratify right-heart consequence → cause-specific treatment → exercise/pregnancy/oxygen and comorbidity handoffs → repeated right-heart and functional receipt → escalation to intervention, surgery or transplant where needed.
Wait, What? The Same Pulmonary Pressure Can Come From Different Diseases
The 2022 ESC/ERS pulmonary-hypertension guidelines classify pulmonary hypertension into major groups because therapy that helps one mechanism can be ineffective or harmful in another. A patient with pulmonary arterial hypertension, a patient with left-heart disease, a patient with severe lung disease and a patient with chronic thromboembolic obstruction do not have the same owner even if all have elevated pulmonary pressures.
Core anti-collapse rules: elevated pulmonary pressure ≠ pulmonary arterial hypertension; echocardiographic estimate ≠ definitive haemodynamic classification; breathlessness ≠ pulmonary hypertension proven; pulmonary hypertension ≠ one medication pathway; right-heart improvement ≠ underlying cause cured.
The Pulmonary Hypertension Tube
Symptoms/risk condition → ECG/echo/imaging/lung evidence → estimate probability → exclude common left-heart/lung causes → ventilation-perfusion or vascular assessment where indicated → right-heart catheterisation for definitive haemodynamics in selected pathways → classify PH group → risk assessment → cause-specific therapy → repeated symptoms/functional class/biomarker/right-heart receipt → intervention/transplant route if progressive.
1. The Owner Is the Pulmonary-Vascular State
The Respiratory Medicine Web owns lung disease broadly. The Cardiovascular Medicine Web owns heart and vascular disease broadly. Pulmonary Hypertension owns the cross-system state where pulmonary vascular pressure and right-heart load become the central clinical problem.
2. The Right Ventricle Is the Main Human Consequence
As resistance in the pulmonary circulation rises, the right ventricle must generate more pressure to maintain flow. Over time it may dilate, weaken or fail. Symptoms such as exertional breathlessness, chest discomfort, fatigue, syncope and oedema can reflect this inability to increase output.
For eduKateAI, pulmonary pressure should therefore remain linked to right-ventricular size/function, cardiac output, symptoms and exercise capacity.
3. Echocardiography Is a Probability Tool
Echocardiography can estimate pulmonary pressures and assess right-heart structure and function, but it does not by itself classify every form of pulmonary hypertension. The diagnostic pathway depends on clinical context and other evidence.
Anti-collapse rule: high estimated pressure on echo ≠ definitive PAH diagnosis.
4. Right-Heart Catheterisation Measures the Haemodynamics Directly
Right-heart catheterisation can directly measure pulmonary artery pressure, filling pressures and cardiac output. In pulmonary arterial hypertension and other selected pathways, these measurements are essential for accurate classification and treatment decisions.
The RFE is not “perform an invasive test”; it is use direct haemodynamics when the result materially changes classification or therapy.
5. Group 1: Pulmonary Arterial Hypertension Is a Specific Disease Family
Pulmonary arterial hypertension includes idiopathic, heritable and associated forms linked to connective-tissue disease, congenital heart disease, portal hypertension, drugs/toxins and other recognised causes.
PAH-specific therapy is chosen according to risk, comorbidity and treatment response. The ESC/ERS framework emphasises structured risk assessment and escalation rather than a single universal drug.
6. Group 2: Left-Heart Disease Changes the Owner
Elevated left-sided filling pressures from heart failure or valve disease can transmit pressure backward into the pulmonary circulation. The primary treatment therefore targets the left-heart disease rather than assuming pulmonary arterial hypertension.
The Heart Failure & Advanced Heart Care Web owns the heart-failure trajectory.
7. Group 3: Lung Disease and Hypoxia Create Another Mechanism
Chronic lung disease and low oxygen can remodel pulmonary vessels and raise pulmonary pressure. The Respiratory Medicine Web owns the underlying lung disease; the pulmonary-hypertension node owns the vascular and right-heart consequence.
8. Group 4: Chronic Thromboembolic Disease Is Potentially Mechanically Treatable
Chronic organised thromboembolic obstruction can produce chronic thromboembolic pulmonary hypertension (CTEPH). Unlike many other pulmonary-hypertension forms, selected patients may benefit from pulmonary endarterectomy or balloon pulmonary angioplasty, with medical therapy used in specific contexts.
Anti-collapse rule: history of pulmonary embolism ≠ CTEPH; CTEPH ≠ lifelong anticoagulation alone.
9. Congenital Heart Disease Can Create Pulmonary Vascular Disease
Long-standing abnormal shunts can expose the pulmonary circulation to excessive flow or pressure. The Congenital Heart Disease & Lifelong Cardiac Care Web owns the congenital anatomy; Pulmonary Hypertension owns the pulmonary-vascular consequence.
10. Risk Assessment Is About the Right Heart and the Human
Risk assessment can combine symptoms, WHO functional class, walking/exercise capacity, biomarkers, imaging and haemodynamics. The ESC/ERS approach uses repeated risk assessment because response to treatment matters.
The route should therefore preserve baseline risk → treatment → follow-up risk state, not simply medication lists.
11. Exercise and Rehabilitation Are Deliberate, Not Generic
Appropriately supervised exercise and rehabilitation can improve function in selected stable patients, while unsafe exertion can provoke syncope or severe symptoms in advanced disease. The Rehabilitation & Allied Health Web owns graded functional recovery.
12. Pregnancy Is a High-Stakes Haemodynamic Handoff
Pregnancy increases blood volume and cardiac output. In some pulmonary-hypertension states, especially PAH, this can be very high risk. Current ESC/ERS guidance emphasises expert counselling and shared decision-making.
The Obstetrics route owns pregnancy care; Pulmonary Hypertension owns the pulmonary-vascular risk that must be transferred into that decision.
13. Advanced Disease Can End in Transplant Evaluation
Progressive right-heart failure despite appropriate therapy may require referral for lung or heart-lung transplantation in selected patients. The Transplantation Medicine Web owns allocation, graft and post-transplant states.
14. Evidence, Uncertainty and Correction
Pulmonary hypertension is unusually vulnerable to misclassification because symptoms are nonspecific and several disease groups overlap. Evidence may include echo, CT, ventilation-perfusion imaging, lung tests, biomarkers, sleep evaluation and invasive haemodynamics.
The correction loop is suspected PH → classify likely mechanism → obtain decisive evidence → treat cause → repeat right-heart/function receipt → reclassify if expected response does not occur.
15. RFE: Did the System Reduce Right-Heart Burden Without Treating the Wrong Disease?
The Medicine RFE asks whether timely, evidence-grounded and ethically authorised help reaches the human and improves outcomes without preventable harm. In pulmonary hypertension, success means correct classification, cause-specific treatment, repeated assessment of right-heart performance and function, appropriate escalation, and preservation of exercise capacity, independence and meaningful life.
eduKateAI Pulmonary Hypertension Tube Card
- TRIGGER: dyspnoea, syncope, chest pain, oedema, RV strain or incidental echo finding?
- PROBABILITY: echo/right-heart findings consistent with PH?
- GROUP: PAH, left heart, lung/hypoxia, thromboembolic or other?
- HAEMODYNAMICS: right-heart catheterisation required/completed?
- RIGHT HEART: RV function, cardiac output and congestion?
- CAUSE: connective tissue, congenital, thromboembolic, lung, left-heart or other?
- RISK: functional class, exercise, biomarkers, imaging and haemodynamics?
- TREATMENT: cause-specific medical, surgical, catheter or supportive route?
- LIFE STATE: exercise, pregnancy, travel and oxygen needs?
- HUMAN RETURN: symptoms, independence, work and quality of life?
Canonical External Sources
Educational boundary: This page explains pulmonary-hypertension information architecture. It does not diagnose pulmonary hypertension, interpret personal echocardiograms or catheterisation results, recommend pulmonary-vasodilator therapy, determine pregnancy safety, or replace specialist cardiopulmonary assessment.
